Safety and Tolerability of Pivmecillinam During More Than Four Decades of Clinical Experience: A Systematic Review
Clinical Infectious Diseases · 2025
DOI: 10.1093/cid/ciae621 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Keith S Kaye und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy, Immunology and Infectious Diseases, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Urinary Tract Infections, Amdinocillin Pivoxil. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UTILITY therapeutics.
Abstract (Originalsprache)
The recent US Food and Drug Administration approval of pivmecillinam—an oral prodrug of the amidinopenicillin antibiotic mecillinam—presents a valuable opportunity to address the need for new treatments for uncomplicated urinary tract infection (uUTI). We report findings of a systematic literature review of the safety profile of pivmecillinam/mecillinam based on more than 40 years’ experience, mainly in Europe and Canada, to describe its tolerability profile and identify any important safety signals. In total, 110 eligible publications were identified describing use of pivmecillinam/mecillinam as monotherapy or in combination, for treatment of uUTI or other infectious conditions. These studies revealed a benign safety and tolerability profile, awareness of which will inform treatment decisions as pivmecillinam is made available in the United States. Together with the evidence for efficacy of, and minimal resistance to, pivmecillinam, the findings of this review support the position of pivmecillinam as a first-line treatment for uUTI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Allergy, Immunology and Infectious Diseases, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.
- Clinical Development, UTILITY therapeutics, London, United Kingdom.
- Clinical Development, Maxel Consulting ApS, Jyllinge, Denmark.
- DTU Biosustain, Technical University of Denmark, Lyngby, Denmark.
- Department of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark.
ORCID-Profile: Keith S Kaye, Anne Santerre Henriksen, Morten Sommer, Niels Frimodt-Møller
Förderung
- UTILITY therapeutics
Zitieren
APA
Kaye, K. S., Santerre Henriksen, A., Sommer, M., & Frimodt-Møller, N. (2025). Safety and Tolerability of Pivmecillinam During More Than Four Decades of Clinical Experience: A Systematic Review. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae621
Vancouver
Kaye KS, Santerre Henriksen A, Sommer M, Frimodt-Møller N. Safety and Tolerability of Pivmecillinam During More Than Four Decades of Clinical Experience: A Systematic Review. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciae621
BibTeX
@article{Kaye2025,
author = {Kaye, Keith S and Santerre Henriksen, Anne and Sommer, Morten and Frimodt-Møller, Niels},
title = {Safety and Tolerability of Pivmecillinam During More Than Four Decades of Clinical Experience: A Systematic Review},
journal = {Clinical Infectious Diseases},
year = {2025},
doi = {10.1093/cid/ciae621}
}
EUVIMED